secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dyne Therapeutics, Inc. (DYN)
CIK:        0001818794
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0000950170-23-037592
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dyne Q2 net loss $64.9M ($1.08/sh); cash $207.7M; clinical data on track for H2 2023
--------------------------------------------------------------------------------

- Net loss of $64.9M ($1.08 per share) vs $52.3M ($1.01) in Q2 2022.
- R&D expenses $59.1M, up from $46.7M; G&A $7.6M vs $6.1M.
- Cash and securities $207.7M as of June 30, 2023; funds operations through 2024.
- Enrollment ongoing in ACHIEVE (DYNE-101, DM1) and DELIVER (DYNE-251, DMD) registrational trials; initial data expected H2 2023.
- EMA granted orphan drug designation for DYNE-101 in DM1; FORCE platform CNS delivery data at ASGCT.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818794/000095017023037592/0000950170-23-037592-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818794/000095017023037592/dyn-20230803.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-037592

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer